Medical network February 21 - spring is the season for systemic allergic diseases, is mainly due to the fog weather in spring is more plus air humidity is bigger, and the influence of factors such as food, animals and plants. Systemic allergic is relatively rare in our country, the market potential for use. According to kang CMH monitoring data show that in 2015 the overall scale of China's systemic allergic drugs (according to the five terminal price calculation, similarly hereinafter) is 4.9 billion yuan, up 5.9% from 2014.
4.9 billion yuan of the overall size, will continue to rise
According to kang CMH monitoring data show that in 2015 the overall scale of China's systemic allergic drugs (according to the five terminal price calculation, similarly hereinafter) is 4.9 billion yuan, up 5.9% from 2014. Is predicted to grow 5.1% in 2016, the overall size of the market, the scale will reach 5.2 billion yuan.
Figure 1 2014-2016 - e systemic allergic drug market size (unit: one hundred million yuan)
Data sources: kang CMH
City level hospital market is active
From five terminals, systemic drug allergy patients preferred or city level hospital, the city level hospital sales contribution in 2015 was 49.4%, in 2016 is expected to decline; The sales contribution of retail pharmacies in 2015 to 24.5%, in 2016 is expected to further improve.
In figure 2, 2014-2016 - e systemic drug allergy medicinal channel sales accounted for
Data sources: kang CMH
Domestic enterprises to dominate the market
From the five terminals, systemic allergic medicinal drugs market mainly by domestic enterprises, including hospital terminal is the most active sales channels, domestic enterprises performance in 2015 domestic enterprises at the county level hospital sales accounted for 84.9%, maximum is higher than other four sales terminal. Foreign companies in the retail terminal sales best and city level hospital, 2015 foreign-invested enterprises in both rose over the previous year, five terminals that foreign firms invested more resources to grab the retail pharmacies and city level hospital.
Figure 3 systemic allergic medicinal drugs in 2014-2015 five terminal market sales proportion of domestic and foreign enterprises
Data sources: kang CMH
Mostly in the top 10 enterprises market concentration is high, the domestic enterprises
, according to kang CMH monitoring data in 2015, systemic allergic drug use five terminal market totaled 49.8% share of the top ten enterprises, market concentration is high. Give priority to with domestic enterprises, foreign-funded enterprises have four; Among them, the foreign capital enterprise bayer pharmaceutical sales share for two consecutive years ranked first, the best products to the retail market, predict 2016 share still showed a trend of growth. Domestic enterprises in the Yangtze river pharmaceutical and hainan split second, three, share ratio of 6.7% and 5.9% respectively, predict 2016 share will be on the rise.
In figure 4, 2015-2016 - e systemic drug allergy medicinal five top 10 enterprises terminal sales accounted for
Data sources: kang CMH
Note: EI in 100 as a benchmark, said category's average level of development; Above average EI > 100 said product development; EI < 100 said product development below the average.
Top 10 brand competition is intense, karry obvious advantages
In the top 10 brand competition, karry temple loratadine tablet dominance, accounted for 10.3% of the market in 2015 ranked the first, market share remained stable; Yangtze river of citrate acid to loratadine tablets to occupy 5.1% of the market, predict 2016 will increase to 6.8% of the market share; Other top 10 brand competition between market share.
In figure 5, 2015-2016 - e systemic allergy medication may need brand share sales
Data sources: kang CMH
Note: EI in 100 as a benchmark, said category's average level of development; Above average EI > 100 said product development; EI < 100 said product development below the average.
|
